Abpro Holdings, Inc. is named in Nasdaq Stock Market LLC’s Form 25 notice concerning removal from listing and registration of its Class A Common Stock and Warrants. The notice states that Nasdaq complied with its rules to strike the securities from listing and/or withdraw registration, and recites the issuer’s compliance with requirements governing voluntary withdrawal.
Abpro Holdings, Inc. (ABPO) reports that on August 25, 2026, Miles Suk voluntarily resigned as Chairman of the Board, effective that date. The company states his resignation was not due to any disagreement regarding operations, policies, or practices, and he will continue to serve as a director. The Board plans to appoint a new Chair at its next regularly scheduled meeting.
In connection with Mr. Suk’s prior resignation as Chief Executive Officer, Abpro terminated his consulting agreement. He is entitled to continued payment of his $300,000 annual consulting fee for 60 days beginning August 19, 2026, resulting in $50,000 of compensatory payments during that period. Other than standard directors’ fees while he remains on the Board, the company reports no further compensatory obligations to him. The company’s common stock and warrants trade on the OTC Pink Ltd. tier following delisting from Nasdaq as of February 23, 2026.
Abpro Holdings, Inc. (ABPO) announced that Chief Executive Officer Miles Suk voluntarily resigned from the CEO role effective August 19, 2026, while remaining on the Board of Directors. The Board appointed M. Fatih Karatas, 47, as Interim Chief Executive Officer, effective August 25, 2026. The company states Mr. Suk’s resignation was not due to any disagreement regarding operations, policies, or practices.
Mr. Karatas brings over 20 years of experience in global finance and investment management, including leadership roles at AIS Advisors, SAASPASS, QInvest, and UBS AG overseeing portfolios exceeding $130 billion. He will serve as interim CEO without compensation for three months, after which a compensation arrangement may be considered. In connection with his resignation as CEO, Mr. Suk’s consulting agreement was terminated, and he is entitled to continued pro-rata payments of his $300,000 annual consulting fee for 60 days, totaling approximately $50,000.
Abpro Holdings, Inc. reported for the quarter ended June 30, 2026 that it remains a development-stage biotech with no product revenue and a continued net loss. Net loss was $0.9 million for the quarter and $2.0 million for the first six months of 2026, compared with losses of $3.0 million and $6.9 million in the prior-year periods, reflecting sharply reduced research and development spending.
Cash increased to $4.2 million at June 30, 2026, largely from $7.3 million of proceeds from issuing 3.16 million shares under a Standby Equity Purchase Agreement, but current liabilities of $8.2 million left a total stockholders’ deficit of $3.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern within one year without additional capital. During the period, Abpro’s shares were delisted from Nasdaq and moved to the OTC Pink Limited Market, which the company notes may adversely affect liquidity and future fund-raising.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of Shares of Common Stock of ABPRO HOLDINGS INC in an amended Schedule 13G filing. The filing states that the Goldman entities have shared voting and dispositive power over 180,690 shares, representing 3.0% of the class, and no sole voting or dispositive power.
The securities are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser and a subsidiary of The Goldman Sachs Group, Inc. The reporting group notes it is reporting ownership of 5 percent or less of ABPRO’s common stock and includes standard disclaimers that certain Goldman Sachs operating units and client or fund accounts may beneficially own securities separately from the reporting units.
Abpro Holdings, Inc. received notice from the Nasdaq Listing and Hearing Review Council that it reaffirmed a prior decision to delist the company’s securities from Nasdaq. The Council cited Abpro’s failure to meet the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline set in a November 10, 2025 panel decision.
Abpro expects Nasdaq to file a Form 25 to delist and deregister its securities under Section 12(b) of the Exchange Act. The company expects its common stock and public warrants to continue quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW,” but warns holders about potentially limited information availability, reduced transparency and liquidity, and greater trading volatility.
Abpro Holdings, Inc. reported a smaller net loss of $1,028 thousand for the quarter ended March 31, 2026, compared with $3,887 thousand a year earlier, as operating expenses fell sharply to $933 thousand from $2,958 thousand.
Cash rose to $5,398 thousand and total assets to $6,865 thousand, mainly from issuing 3,162,785 shares under its Standby Equity Purchase Agreement for gross proceeds of $7,264 thousand. Despite this, current liabilities of $9,117 thousand and a stockholders’ deficit of $2,252 thousand leave the company with negative equity.
Management states there is substantial doubt about Abpro’s ability to continue as a going concern within one year without additional financing. Its common stock was delisted from Nasdaq effective February 23, 2026 and now trades on the OTC Pink Limited market under “ABPO,” which may further hinder capital-raising efforts.
Abpro Holdings, Inc. filed an amended annual report to add Part III disclosures on directors, executive pay, ownership, related-party transactions, and auditor fees. The company’s common stock and warrants have been delisted from Nasdaq and trade on the OTC Pink tier as of February 23, 2026.
The board held 18 meetings in 2025, with all directors attending at least 75% of sessions, and three of four directors deemed independent. CEO Jin Wook (Miles) Suk earned a $250,000 salary and RSU awards valued at $261,792 in 2025 and is engaged through a consulting agreement providing a $300,000 annual fee and 500,000 RSUs, plus a change-of-control payout formula.
Former CEO Ian Chan and former Chief Medical Officer Robert Markelewicz received lower 2025 cash compensation before their terminations. As of March 30, 2026, 5,896,048 shares of common stock were outstanding, with sizeable stakes held by Abpro Bio International Inc., Atlantic Coastal Acquisition Management II LLC, and Ian Chan. The filing also outlines a clawback policy adopted in 2023 and notes 2025 audit and related fees totaling $483,250 for Wolf & Company and Marcum.
Abpro Holdings, Inc. is an early-stage biotechnology company developing next‑generation multispecific antibody drugs for cancer and eye diseases, built on its DiversImmune and TetraBi platforms. The company completed a reverse recapitalization with SPAC Atlantic Coastal Acquisition Corp. II in November 2024 and effected a 1‑for‑30 reverse stock split effective October 31, 2025.
Abpro’s lead oncology asset ABP‑102, partnered worldwide with Celltrion, received FDA clearance of its IND on January 6, 2026, enabling a Phase 1 trial in HER2‑positive solid tumors. Ophthalmology candidate ABP‑201 is licensed regionally to Abpro Bio, with additional T‑cell engager programs ABP‑110 and ABP‑150 in pre‑clinical development.
The business is highly capital constrained. Management discloses substantial doubt about its ability to continue as a going concern and relies on external financing. A $50 million Standby Equity Purchase Agreement with YA II PN, Ltd. funded approximately $1.0 million in 2025 and $6.7 million of net proceeds in early 2026, but became unavailable after Abpro’s common stock was delisted from Nasdaq on February 23, 2026 and moved to the OTC Pink Limited Market. As of June 30, 2025, non‑affiliate market value was about $9.3 million, and 5,896,048 common shares were outstanding as of March 30, 2026.